Ausgewählte Publikationen Mykobakteriologie und NZM

  1. Identification of novel scaffolds targeting Mycobacterium tuberculosis.
    Dal Molin M, Selchow P, Schäfle D, Tschumi A, Ryckmans T, Laage-Witt S, Sander P
    J Mol Med 97:1601-1613 (2019)
  2. Whole genome sequencing for drug resistance profile prediction in Mycobacterium tuberculosis.
    Gygli S, Keller P, Ballif M, Blöchliger N, Hömke R, Reinhard M, Loiseau C, Ritter C, Sander P, Borrell S, Collantes J, Avihingsanon A, Gnokoro J, Yotebieng M, Egger M, Gagneux S, Böttger EC (2019)
    Antimicrob Agents Chemother 63: e02175-18
  3. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multi-centre cohort study.
    Zürcher K, Ballif M, Fenner L, Borrell S, Keller PM, Gnokoro J, Marcy O, Yotebieng M, Diero L, Carter EJ, Rockwood N, Wilkinson RJ, Cox H, Ezati N, Abimiku AG, Collantes J, Avihingsanon A, Kawkitinarong K, Reinhard M, Hömke R, Huebner R, Gagneux S, Böttger EC, Egger M (2019)
    Lancet Infect Dis 19: 298-307
  4. Increased drug permeability of a stiffened mycobacterial outer membrane in cells lacking MFS transporter Rv1410 and lipoprotein LprG.
    Hohl M, Remm S, Eskandarian HA, Dal Molin M, Arnold FM, Hürlimann LM, Krügel A, Fantner GE, Sander P, Seeger MA (2019)
    Mol Microbiol 111: 1263-1282
  5. A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study.
    Walker TM, Merker M, Knoblauch AM, Helbling P, Schoch OD, van der Werf MJ, Kranzer K, Fiebig L, Kröger S, Haas W, Hoffmann H, Indra A, Egli A, Cirillo DM, Robert J, Rogers TR, Groenheit R, Mengshoel AT, Mathys V, Haanperä M, Soolingen DV, Niemann S, Böttger EC, Keller PM; MDR-TB Cluster Consortium (2018)
    Lancet Infect Dis 18: 431-440
  6. Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement.
    van Ingen J, Aksamit T, Andrejak C, Böttger EC, Cambau E, Daley CL, Griffith DE, Guglielmetti L, Holland SM, Huitt GA, Koh WJ, Lange C, Leitman P, Marras TK, Morimoto K, Olivier KN, Santin M, Stout JE, Thomson R, Tortoli E, Wallace RJ Jr, Winthrop KL, Wagner D; for NTM-NET (2018)
    Eur Respir J 51: 1800170
  7. The role of antibiotic-target-modifying and antibiotic-modifying enzymes in Mycobacterium abscessus drug resistance.
    Luthra S, Rominski A, Sander P (2018)
    Front Microbiol 9: 2179
  8. Molecular mechanisms of intrinsic streptomycin resistance in Mycobacterium abscessus.
    Dal Molin M, Gut M, Rominski A, Haldimann K, Becker K, Sander P (2018)
    Antimicrob Agents Chemother 62: e01427-17
  9. Global outbreak of severe Mycobacterium chimaera disease after cardiac surgery: a molecular epidemiological study.
    van Ingen J, Kohl TA, Kranzer K, Hasse B, Keller P, Szafrańska AK, Hillemann D, Chand M, Schreiber PW, Sommerstein R, Berger C, Genoni M, Rüegg C, Troillet N, Widmer AF, Becker SL, Herrmann M, Eckmanns T, Haller S, Höller C, Debast SB, Wolfhagen MJ, Hopman J, Kluytmans J, Langelaar M, Notermans DW, ten Oever J, van den Barselaar P, Vonk AB, Vos MC, Ahmed N, Brown T, Crook D, Lamagni T, Phin N, Smith G, Zambon M, Serr A, Götting T, Ebner W, Thürmer A, Utpatel C, Spröer C, Bunk B, Nübel U, Bloemberg GV, Böttger EC, Niemann S, Wagner D, Sax H (2017)
    Lancet Infect Dis 17: 1033-1041
  10. Development of a novel lead that targets M. tuberculosis polyketide synthase 13.
    Aggarwal A, Parai MK, Shetty N, Wallis D, Woolhiser L, Hastings C, Dutta NK, Galaviz S, Dhakal RC, Shrestha R, Wakabayashi S, Walpole C, Matthews D, Floyd D, Scullion P, Riley J, Epemolu O, Norval S, Snavely T, Robertson GT, Rubin EJ, Ioerger TR,  Sirgel FA, van der Merwe R, van Helden PD, Keller P, Böttger EC, Karakousis PC, Lenaerts AJ, Sacchettini JC (2017)
    Cell 170: 249-259
  11. Effect of β-lactamase production and β-lactam instability on MIC testing results of Mycobacterium abscessus.
    Rominski A, Schultess B, Müller D, Keller P, Sander P (2017)
    J Antimicrob Chemother 72: 3070-3078
  12. Lipoprotein glycosylation by protein-O-mannosyltransferase (MAB_1122c) contributes to low cell envelope permeability and antibiotic resistance in Mycobacterium abscessus.
    Becker K, Haldimann K, Selchow P, Reinau LM, Dal Molin M, Sander P (2017)
    Frontiers Microbiology 8: 2123
  13. Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591.
    Rominski A, Roditscheff A, Selchow P, Böttger EC, Sander P (2017)
    J Antimicrob Chemother 72: 376-384
  14. Elucidation of Mycobacterium abscessus aminoglycoside and capreomycin resistance by targeted deletion of three putative resistance genes.
    Rominski A, Selchow P, Becker K, Brülle JK, Dal Molin M, Sander P (2017)
    J Antimicrob Chemother 72: 2191-2200
  15. Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives.
    Schön T, Miotto P, Köser CU, Viveiros M, Böttger EC, Cambau E (2017)
    Clin Microbiol Infect 23: 154-160
  16. Non-mutational compensation of the fitness cost of antibiotic resistance in mycobacteria by overexpression of tlyA rRNA methylase.
    Freihofer P, Akbergenov R, Teo Y, Juskeviciene R, Anderson DI, Böttger EC (2016)
    RNA 22: 1836-1843
  17. Standard genotyping overestimates transmission of Mycobacterium tuberculosis among immigrants in a low-incidence country.
    Stucki D, Ballif M, Egger M, Furrer H, Altpeter E, Battegay M, Droz S, Bruderer T, Coscolla M, Borrell S, Zürcher K, Janssens JP, Calmy A, Mazza Stalder J, Jaton K, Rieder HL, Pfyffer GE, Siegrist HH, Hoffmann M, Fehr J, Dolina M, Frei R, Schrenzel J, Böttger EC, Gagneux S, Fenner L (2016)
    J Clin Microbiol 54: 1862-1870
  18. Diagnostic molecular mycobacteriology in regions with low tuberculosis endemicity: combining real-time PCR assays for detection of multiple mycobacterial pathogens with line probe assays for identification of resistance mutations.
    Deggim-Messmer V, Bloemberg GV, Ritter C, Voit A, Hömke R, Keller PM, Böttger EC (2016)
    EBioMedicine 9: 228-237
  19. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus Statement.
    Dominguez J, Böttger EC, Cirillo D, Cobelens F, Eisenach KD, Gagneux S, Hillemann D, Horsburgh R,Molina-Moya B, Niemann S, Tortoli E, Whitelaw A, Lange C (2016)
    Int J Tuberc Lung Dis 20: 24-42
  20. Mycobacterium tuberculosis drug resistance testing: challenges, recent developments and perspectives.
    Schön T, Miotto P, Köser CU, Viveiros M, Böttger EC, Cambau E (2016)
    Clin Microbiol Infect 23: 154-160
  21. A mutation associated with clofazimine and bedaquiline cross-resistance in MDRTB following bedaquiline treatment.
    Somoskovi A, Bruderer V, Hömke R, Bloemberg GV, Böttger EC (2015)
    Eur Respir J 45: 554-557
  22. Aminoglycoside modifying enzymes determine the innate susceptibility to aminoglycoside antibiotics in rapidly growing mycobacteria.
    Maurer F, Bruderer V, Castelberg C, Ritter C, Scherbakov D, Bloemberg G, Böttger E (2015)
    J Antimicrob Chemother 70: 1412-1419
  23. Prolonged outbreak of Mycobacterium chimaera infection after open chest heart surgery.
    Sax H, Bloemberg G, Hasse B, Sommerstein R, Kohler P, Achermann Y, Rössle M, Falk V, Kuster SP, Böttger EC, Weber R (2015)
    Clin Infect Dis 61: 67-75
  24. In vitro and in vivo evaluation of synergism between anti-tubercular spectinamides and non-classical tuberculosis antibiotics.
    Bruhn DF, Schermann M, Liu J, Shcherbakov D, Meibohm B, Böttger EC, Lenaerts AJ, Lee RE (2015)
    Sci Rep 5: 13985
  25. Determination of MIC distribution and epidemiological cut-off values for bedaquiline and delamanid in Mycobacterium tuberculosis using MGIT 960/ TB eXiST.
    Keller P, Hömke R, Ritter C, Valsesia G, Bloemberg GV, Böttger EC (2015)
    Antimicrob Agents Chemother 59: 4352-4355
  26. Health-care associated prosthetic heart valve, aortic vascular graft, and disseminated Mycobacterium chimaera infections subsequent to open heart surgery.
    Kohler P, Kuster SP, Bloemberg GV, Schulthess B, Frank M, Tanner FC, Rössle M, Böni C, Falk V, Wilhelm MJ, Sommerstein R, Achermann Y, ten Oever J, Debast SB, Wolfhagen MJHM, Brandon Bravo Bruinsma GJ, Vos MC, Bogers A, Serr A, Beyersdorf F, Sax H, Böttger EC, Weber R, van Ingen J, Wagner D, Hasse B (2015)
    Eur Heart J 36: 2745-2753
  27. Revisiting susceptibility testing in multidrug resistant tuberculosis by a standardized quantitative phenotypic assessment in a European multicenter study.
    Cambau E, Viveiros M, Machado D, Raskine L, Ritter C, Tortoli E, Mattys V, Hoffner S, Richter E, Perez-del-Molino L, Cirillo D, van Soolingen D, Böttger EC (2015)
    J Antimicrob Chemother 70: 686-696
  28. Evaluation of carbapenemase screening and confirmation tests in Enterobacteriaceae and development of a practical diagnostic algorithm.
    Maurer F, Castelberg C, Quiblier C, Bloemberg G, Hombach M (2015)
    J Clin Microbiol 53: 95-104
  29. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis.
    Bloemberg GV, Keller P, Stucki D, Trauner A, Borrell S, Latshang T, Coscolla N, Rothe T, Hömke R, Ritter C, Feldmann J, Schulthess B, Gagneux S, Böttger EC (2015)
    N Engl J Med 373: 1986-1988
  30. Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis.
    Sander P, Clark S, Petrera A, Vilaplana C, Meuli M, Selchow P, Zelmer A, Mohanan D, Andreu N, Rayner E, Dal Molin M, Bancroft GJ, Johansen P, Cardona PJ, Williams A, Böttger EC (2015)
    Vaccine 33: 1353-1359
  31. Evaluation of the AID TB Resistance line probe assay for rapid detection of genetic alterations associated with Mycobacterium tuberculosis drug resistance.
    Ritter C, Lucke K, Sirgel FA, Warren RW, van Helden PD, Böttger EC, Bloemberg GV (2014)
    J Clin Microbiol 52: 940-946
  32. Transmission of multidrug-resistant tuberculosis in low-incidence setting, Switzerland, 2006 to 2012.
    Somoskovi A, Helbling P, Deggim V, Hömke R, Ritter C, Böttger EC (2014)
    Euro Surveill 19: pii=20736
  33. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus.
    Maurer F, Castelberg C, Quiblier C, Böttger E, Somoskövi A (2014)
    J Antimicrob Chemother 69: 1559-1563
  34. Lack of antimicrobial bactericidal activity in Mycobacterium abscessus.
    Maurer F, Bruderer V, Ritter C, Castelberg C, Bloemberg GV, Böttger EC (2014)
    Antimicrob Agents Chemother 58: 3828-3836
  35. Postsurgical wound infections due to rapidly growing myciobacteria in Swiss medical tourists following cosmetic surgery in Latin America between 2012 and 2014.
    Maurer FP, Castelberg C, von Braun A, Wolfensberger A, Bloemberg GV, Böttger EC, Somoskovi A (2014)
    Euro Surveill 19: pii: 20905
  36. High level resistance to isoniazid and ethionamide in multidrug resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations.
    Machado D, Perdigao J, Ramos J, Couto I, Portugal I, Ritter C, Böttger EC, Viveiros M (2013)
    J Antimicrob Chemother 68: 1728-1732
  37. Prosthetic valve endocarditis and bloodstream infection due to Mycobacterium chimaera.
    Achermann Y, Rössle M, Hoffmann M, Deggim V, Kuster S, Zimmermann DR, Bloemberg G, Hombach M, Hasse B (2013)
    J Clin Microbiol 51: 1769-1773
  38. Evaluation of Cobas TaqMan MTB for direct detection of the Mycobacterium tuberculosis complex in comparison with Cobas Amplicor MTB.
    Bloemberg GV, Voit A, Ritter C, Deggim V, Böttger EC (2013)
    J Clin Microbiol 51: 2112-2117
  39. Integrating the Xpert MTB/RIF assay into a diagnostic workflow for rapid detection of Mycobacterium tuberculosis in a low-prevalence area.
    Deggim V, Somoskövi A, Voit A, Böttger EC, Bloemberg GV (2013)
    J Clin Microbiol 51: 2396-2399
  40. HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosis.
    Fenner L, Egger M, Bodmer T, Furrer H, Ballif M, Battegay M, Helbling P, Fehr J, Gsponer T, Rieder HL, Zwahlen M, Hoffmann M, Bernasconi E, Cavassini M, Calmy A, Dolina M, Frei R, Janssens JP, Borrell S, Stucki D, Schrenzel J, Bötter EC, Gagneux S (2013)
    PLoS Genet 9: e1003318
  41. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST.
    Hombach M, Somoskövi A, Hömke R, Ritter C, Böttger EC (2013)
    Int J Med Microbiol 303: 270-276
  42. The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks.
    Sirgel FA, Warren RM, Böttger EC, Klopper M, Victor TC, van Helden PD (2013)
    PLoS One 8: e59414
  43. Transmission of M. abscessus in patients with cystic fibrosis.
    Böttger EC (2013)
    Lancet 382: 503-504
  44. Automated quantitative drug susceptibility testing of nontuberculous mycobacteria using MGIT960 / EpiCenter TBeXIST.
    Lucke K, Hombach M, Friedel U, Ritter C, Böttger EC (2012)
    J Antimicrob Chemother 67: 154-158
  45. Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of Mycobacterium abscessus in the presence of inducible erm(41) methylase.
    Maurer F, Rüegger V, Ritter C, Bloemberg GV, Böttger EC (2012)
    J Antimicrob Chemother 67: 2606-2611
  46. embB306 mutations as molecular indicators to predict ethambutol susceptibility in Mycobacterium tuberculosis.
    Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC (2012)
    Chemotherapy 58: 358-363
  47. Mycobacterium tuberculosis transmission in a low-incidence country: role of immigration and HIV infection.
    Fenner L, Gagneux S, Helbling P, Battegay M, Rieder H, Pfyffer G, Zwahlen M, Furrer H, Siegrist H, Fehr J, Dolina M, Calmy A, Stucki D, Jaton K, Janssens JP, Mazza Stalder J, Bodmer T, Ninet B, Böttger EC, Egger M (2012)
    J Clin Microbiol 50: 388-395
  48. Tuberculosis in HIV-negative and HIV-infected patients in a low-incidence country: clinical characteristics and treatment outcome.
    Fenner L, Gagneux S, Janssens JP, Fehr J, Cavassini M, Hoffman M, Bernasconi E, Schrenzel J, Bodmer T, Böttger EC, Helbling P, Egger M (2012)
    PLoS One 7: e34186
  49. Mycobacterium tuberculosis population structure determines the outcome of genetic based second-line drug resistance testing.
    Streicher E, Bergval I, Dheda K, Böttger EC, Gey van Pitius N, Bosman M, Coetzee G, Anthony R, van Helden PD, Victor TC, Warren RM (2012)
    Antimicrob Agents Chemother 56: 2420-2427
  50. Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis.
    Fenner L, Egger M, Bodmer T, Altpeter E, Zwahlen M, Jaton K, Pfyffer GE, Borrell S, Dubuis O, Bruderer T, Siegrist HH, Furrer H, Calmy A, Fehr J, Stalder JM, Ninen B, Böttger EC, Gagneux S (2012)
    Antimicrob Agents Chemother 56: 3047-3053
  51. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.
    Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC (2012)
    J Antimicrob Chemother 67: 1088-1093
  52. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis.
    Sirgel FA, Tait M, Warren RM, Streicher EM, Böttger EC, van Helden PD, Gey van Pittius NC, Coetzee G, Hoosain EY, Chabula-Nxiweni M, Hayes C, Victor TC, Trollip A (2012)
    Microb Drug Resist 18: 193-197